Haloperidol withdrawal and weight changes in autistic children

Area of Science:

• Pediatric Psychiatry
• Neurodevelopmental Disorders
• Pharmacology

Background:

• Autistic disorder is a complex neurodevelopmental condition affecting social interaction and communication.
• Haloperidol, a typical antipsychotic, is sometimes used off-label to manage behavioral symptoms in autistic children.
• Concerns exist regarding the long-term metabolic effects, particularly weight changes, associated with antipsychotic use in pediatric populations.

Purpose of the Study:

• To evaluate the long-term effects of haloperidol on body weight in children diagnosed with autistic disorder.
• To assess weight changes during a haloperidol treatment period and subsequent drug withdrawal phase.

Main Methods:

• A cohort of 30 children (ages 3.08-8.42 years) with autistic disorder received haloperidol (0.25-3.50 mg/day) for 6 months.
• Body weight was measured at the end of the 6-month treatment and after a 4-week drug withdrawal period.
• Weight was monitored monthly in a subsample (n=8) during treatment and withdrawal.

Main Results:

• No significant difference was found between mean weights at the end of haloperidol treatment (24.799 ± 9.741 kg) and after 4 weeks of withdrawal (24.644 ± 9.833 kg).
• Weight briefly increased in the first week of discontinuation but subsequently decreased during the following weeks of withdrawal.
• In the subsample, weight gain was more pronounced during the month following the resumption of haloperidol treatment compared to the period before drug withdrawal.

Conclusions:

• Long-term haloperidol treatment for autistic disorder in this pediatric cohort did not result in significant sustained weight gain.
• Observed weight fluctuations during drug withdrawal appear transient.
• Further research is warranted to fully understand the complex relationship between haloperidol, autistic disorder, and metabolic changes in children.